Patients with a solid tumor cancer are needed for a study to research a combination of an experimental drug by itself or in combination with 2 FDA approved drugs.

IRB/UVA Tracking #
22642
Principal Investigator
Matthew J Reilley
Contact
Sallie Mannen
Contact Email
Contact Phone
434.297.5724
Official Trial Title
A phase 1/1b, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1454 alone and in combination with ipilimumab and nivolumab
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a solid tumor. The purpose of this study to evaluate 1 experimental drug (TP-1454) alone or in combination with 2 FDA approved drugs (ipilimumab and nivolumab) in patients with a solid tumor cancer. The experimental drug dose, safety, and the effects of the drug combinations will be evaluated for this study.

Participation is approximately 4 months of drug treatment and possibly longer, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04328740

Compensation

$50 per study visit. Reimbursement: Up to $175 for hotel stay per night.